EP2449385A1 - Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë - Google Patents

Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë

Info

Publication number
EP2449385A1
EP2449385A1 EP10729860A EP10729860A EP2449385A1 EP 2449385 A1 EP2449385 A1 EP 2449385A1 EP 10729860 A EP10729860 A EP 10729860A EP 10729860 A EP10729860 A EP 10729860A EP 2449385 A1 EP2449385 A1 EP 2449385A1
Authority
EP
European Patent Office
Prior art keywords
markers
polypeptide
sample
absence
renal failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10729860A
Other languages
German (de)
English (en)
Inventor
Harald Mischak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaiques Diagnostics and Therapeutics AG
Original Assignee
Mosaiques Diagnostics and Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG
Priority to EP10729860A priority Critical patent/EP2449385A1/fr
Publication of EP2449385A1 publication Critical patent/EP2449385A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Definitions

  • the present invention relates to the diagnosis of acute renal failure.
  • Acute renal failure is characterized by an abrupt decrease in kidney function.
  • causes of the abrupt loss of function of the kidney include a lack of supply of kidney tissue with oxygen, an accidental or surgical fluid loss, the presence of sepsis or drug incompatibility (Lameire et al., Lancet, 2005, Vol. 365, page 417-430, Schrier and Wang, N Engl J Med, 2004, Vol. 351, pages 159-169, Thadhani et al., N Engl J Med, 1996, Vol. 334, pages 1448-1460).
  • the proximal tubule cells are damaged in the course of which mucoprotein cylinders are formed by the cells. These then lead to a loss of renal function via obstruction (Patel et al., Lancet, 1964, BD 29, pages 457-461).
  • Acute renal failure can only be detected late by an increase in serum creatinine (Herget-Rosenthal, Lancet, 2005, Vol. 365, pages 1205-1206, Mehta et al., Crit Care, 2007, Vol. 11, R31).
  • efforts have been made in recent years to identify diagnostic markers which allow a reliable diagnosis of acute renal failure prior to clinical manifestation (Vaidya et al., Clin Transl. Sei, 2008, Vol. 1, page 200-208).
  • biomarker candidates include: neutrophilic gelatinase-associated lipocalin, Kidney Injector Molecule-1, N-acetyl-beta-D-glucoaminidase, interleukin-18 and cystatin C (Nguyen, Pediatric Nephral, 2008, Bd. 23, pages 2151-2157). Due to the heterogeneous nature of acute renal failure, however, these markers also do not adequately form the disease.
  • the object is achieved by a method for diagnosing acute renal failure, comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, wherein the polypeptide markers are selected from the markers shown in Table 1 by values for the molecular masses and the migration time are characterized.
  • Table 1 List of markers that enable the early diagnosis of Acute Renal Failure in a multi-marker model.
  • amino acid sequence is known. This is listed in Table 2 together with the associated precursor protein.
  • AKI Acute Kidney Insufficiency
  • the evaluation of the measured polypeptides can be based on the presence or absence or amplitude of the markers taking into account the following limits:
  • Specificity is defined as the number of actual negative samples divided by the sum of the number of actual negatives and the number of false positives. A specificity of 100% means that a test identifies all healthy persons as healthy, i. no healthy person is identified as ill. This does not say anything about how well the test detects sick patients.
  • Sensitivity is defined as the number of actual positive samples divided by the sum of the number of actual positives and the number of false negatives. A sensitivity of 100% means that the test is all Sick recognizes. He does not say how well the test detects healthy people.
  • the markers according to the invention make it possible to achieve a specificity of at least 70%, preferably at least 80%, more preferably 85%, for acute renal failure.
  • the markers according to the invention make it possible to achieve a sensitivity of at least 70%, preferably at least 80%, more preferably 85%, for acute renal failure.
  • the migration time is determined by capillary electrophoresis (CE) - e.g. in example under point 2 - determined.
  • CE capillary electrophoresis
  • a 90 cm long glass capillary with an inner diameter (ID) of 50 ⁇ m and an outer diameter (OD) of 360 ⁇ m is operated at an applied voltage of 30 kV.
  • the eluent used is, for example, 30% methanol, 0.5% formic acid in water.
  • CE migration time can vary. Nevertheless, the order in which the polypeptide labels elute is typically the same for each CE system used under the conditions indicated. To even out any differences in migration time, the system can be normalized using standards for which migration times are known. These standards may e.g. be the polypeptides given in the examples (see example point 3). Variation in CE time is relatively small between individual measurements, typically in the range of ⁇ 2 min, preferably in the range of ⁇ 1 min, more preferably ⁇ 0.5 min, even more preferably ⁇ 0.2 min or 0.1 minute
  • the characterization of the polypeptides shown in Tables 1 to 4 was determined by capillary electrophoresis mass spectrometry (CE-MS), a procedure described in detail, for example, by Neuhoff et al. (Rapid communications in mass spectrometry, 2004, Vol. 20, pages 149-156).
  • CE-MS capillary electrophoresis mass spectrometry
  • the variation of molecular masses between individual measurements or between different mass spectrometers is relatively small with exact calibration, typically in the range of ⁇ 0.1%, preferably in the range of ⁇ 0.05%, more preferably ⁇ 0.03%, even more preferably ⁇ 0.01% or 0.005%.
  • polypeptide markers according to the invention are proteins or peptides or degradation products of proteins or peptides. They may be chemically modified, e.g. by post-translational modifications such as glycation, phosphorylation, alkylation or disulfide bridging, or by other reactions, e.g. in the context of mining, to be changed. In addition, the polypeptide markers may also be chemically altered as part of the purification of the samples, e.g. oxidized, be.
  • polypeptide markers molecular mass and migration time
  • polypeptides of the invention are used to diagnose acute renal failure.
  • Diagnosis is the process of gaining knowledge by assigning symptoms or phenomena to a disease or injury.
  • the presence or absence of certain polypeptide markers is also used for differential diagnosis.
  • the presence or absence of a polypeptide marker can be measured by any method known in the art. Methods that can be used are exemplified below.
  • a polypeptide marker is present when its reading is at least as high as the threshold. If its reading is below that, the polypeptide marker is absent.
  • the threshold can either be through the sensitivity of the measuring method (detection limit) or defined on the basis of experience.
  • the threshold is preferably exceeded when the sample reading for a given molecular mass is at least twice that of a blank (e.g., only buffer or solvent).
  • the polypeptide marker (s) is / are used to measure its presence or absence, the presence or absence being indicative of the early diagnosis of acute renal failure.
  • polypeptide markers that are typically present in individuals with chronic kidney disease, but are less common or non-existent in individuals without acute renal failure.
  • polypeptide markers that are present in patients with acute renal failure but are not or only rarely present in patients with chronic kidney disease.
  • amplitude markers can also be used for diagnosis.
  • Amplitude markers are used in a manner that does not determine the presence or absence, but decides the magnitude of the signal (amplitude) in the presence of the signal in both groups.
  • the tables show the mean amplitudes of the corresponding signals (characterized by mass and migration time) over all measured samples. Two nomination procedures are possible to achieve comparability between differently concentrated samples or different measurement methods. In the first approach, all peptide signals of a sample are normalized to a total amplitude of 1 million counts. The respective mean amplitudes of the single markers are therefore given as parts per million (ppm).
  • amplitude markers via an alternative standardization procedure: in this case, all peptide signals of a sample are scaled with a common normalization factor. For this purpose, a linear regression is formed between the peptide amplitudes of the individual samples and the reference values of all known polypeptides. The increase in the regression line just corresponds to the relative concentration and is used as a normalization factor for this sample.
  • the decision to make a diagnosis depends on how high the amplitude of the respective polypeptide markers in the patient sample is compared to the mean amplitudes in the control group or the "sick" group. If the value is close to the mean amplitude of the "sick" group, it is to be assumed that there is an acute renal failure, it corresponds more to the mean amplitudes of the control group, is not to be assumed by acute renal failure.
  • the distance to the mean amplitude can be interpreted as a probability of belonging to a group.
  • a frequency marker is a variant of the amplitude marker, in which the amplitude is low in some samples. It is possible to convert such frequency markers into amplitude markers in which, in the calculation of the amplitude, the corresponding samples in which the marker is not found, with a very small amplitude - in the range of the detection limit - is included in the calculation.
  • the individual from whom the sample is derived, in which the presence or absence of one or more polypeptide markers is determined, can be any individual in whom acute renal failure can occur.
  • the subject is a mammal, most preferably a human.
  • the sample measuring the presence or absence of the polypeptide marker (s) of the invention may be any sample recovered from the subject's body.
  • the sample is a sample having a polypeptide composition suitable for making statements about the condition of the individual.
  • it may be blood, urine, synovial fluid, tissue fluid, body secretions, sweat, cerebrospinal fluid, lymph, intestinal, gastric, pancreatic, bile, tear fluid, tissue sample, sperm, vaginal fluid or stool sample.
  • it is a liquid sample.
  • the sample is a urine sample.
  • Urine samples may be known as known in the art.
  • a mid-jet urine sample is used.
  • the urine sample may e.g. by means of a catheter or also with the aid of a urination apparatus, as described in WO 01/74275.
  • the presence or absence of a polypeptide marker in the sample can be determined by any method known in the art suitable for measuring polypeptide markers. Those skilled in such methods are known. In principle, the presence or absence of a polypeptide marker can be determined by direct methods such as e.g. Mass spectrometry, or indirect methods, e.g. by ligands.
  • the sample of the individual may be analyzed prior to the measurement of the presence or absence of the or the polymer.
  • Peptide markers pretreated by any suitable means and, for example, be purified or separated.
  • the treatment may include, for example, purification, separation, dilution or concentration.
  • the methods may be, for example, centrifugation, filtration, ultrafiltration, dialysis, precipitation or chromatographic methods such as affinity separation or separation by ion exchange chromatography, or electrophoretic separation.
  • a subsample means that the sample has been divided into several parts that differ. In a simple form, this may be e.g. is a membrane filtration that separates larger and smaller ingredients of the sample into two subsamples.
  • it may be a chromatographic separation that separates the sample into a plurality of subsamples ("fractions").
  • the sample is separated by electrophoresis prior to its measurement, purified by ultracentrifugation and / or separated by ultrafiltration into fractions containing polypeptide labels of a specific molecular size.
  • a mass spectrometric method is used to determine the presence or absence of a polypeptide marker, this Procedure can be preceded by a purification or separation of the sample.
  • the mass spectrometric analysis has the advantage over current methods that the concentration of many (> 100) polypeptides of a sample can be determined by a single analysis. Any type of mass spectrometer can be used. With mass pectrometry it is possible to routinely measure 10 fmoles of a polypeptide marker, ie 0.1 ng of a 10 kDa protein with a measurement accuracy of approximately ⁇ 0.01% from a complex mixture. In mass spectrometers, an ion-forming unit is coupled to a suitable analyzer.
  • electrospray ionization (ESI) interfaces are most commonly used to measure ions from liquid samples
  • matrix assisted laser desorption / ionization (MALDI) technique is used to measure ions from a sample crystallized with a matrix.
  • ESI electrospray ionization
  • MALDI matrix assisted laser desorption / ionization
  • quadrupoles, ion traps or time-of-flight (TOF) analyzers can be used to analyze the resulting ions.
  • electrospray ionization the molecules present in solution i.a. under the influence of high voltage (e.g., 1-8 kV) to form charged droplets which become smaller by evaporation of the solvent.
  • high voltage e.g. 1-8 kV
  • Coulomb explosions lead to the formation of free ions, which can then be analyzed and detected.
  • TOF analyzers have a very high scanning speed and achieve a very high resolution.
  • Preferred methods for determining the presence or absence of polypeptide markers include gas phase ion spectrometry, such as laser desorption / ionization mass spectrometry, MALDI-TOF-MS, SELDI-TOF-MS (Surface enhanced laser desorption ionization), LC-MS (liquid chromatography-mass spectrometry), 2D-PAGE-MS and capillary electrophoresis mass spectrometry (CE-MS). All of the methods mentioned are known to the person skilled in the art.
  • gas phase ion spectrometry such as laser desorption / ionization mass spectrometry, MALDI-TOF-MS, SELDI-TOF-MS (Surface enhanced laser desorption ionization), LC-MS (liquid chromatography-mass spectrometry), 2D-PAGE-MS and capillary electrophoresis mass spectrometry (CE-MS). All of the methods mentioned are known to the person skilled in the art.
  • CE-MS in which capillary electrophoresis is coupled with mass spectrometry. This process is described in detail, for example, in German patent application DE 10021737, in Kaiser et al. (J. Chromatogr. A 1 2003, Vol. 1013: 157-171, and Electrophoresis, 2004, 25: 2044-2055) and in Wittke et al. (J. Chromatogr. A 1 2003, 1013: 173-181).
  • the CE-MS technique allows to determine the presence of several hundreds of polypeptide markers of a sample simultaneously in a short time, a small volume and high sensitivity. After a sample has been measured, a pattern of the measured polypeptide markers is prepared. This can be compared with reference patterns of ill or healthy individuals. In most cases, it is sufficient to use a limited number of polypeptide markers for the diagnosis of acute renal failure. More preferred is a CE-MS method which includes CE coupled online to an ESI-TOF-MS.
  • solvents include acetonitrile, methanol and the like.
  • the solvents may be diluted with water and an acid (e.g., 0.1% to 1% formic acid) added to protonate the analyte, preferably the polypeptides.
  • Capillary electrophoresis makes it possible to separate molecules according to their charge and size. Neutral particles migrate at the rate of electroosmotic flow upon application of a current, cations are accelerated to the cathode and anions are retarded.
  • the advantage of capillaries in electrophoresis is the favorable ratio of surface area to volume, which enables a good removal of the Joule heat arising during the current flow. This in turn allows the application of high voltages (usually up to 30 kV) and thus a high separation efficiency and short analysis times.
  • quartz glass capillaries with internal diameters of typically 50 to 75 ⁇ m are normally used. The used lengths are 30-100 cm.
  • the capillaries usually consist of plastic-coated quartz glass.
  • the capillaries may be both untreated, i. on the inside show their hydrophilic groups, as well as be coated on the inside. A hydrophobic coating can be used to improve the resolution.
  • a pressure which is typically in the range of 0-1 psi may also be applied. The pressure can also be created during the separation or changed during the process.
  • the markers of the sample are separated by capillary electrophoresis, then directly ionized and transferred online to a mass spectrometer coupled thereto for detection.
  • polypeptide markers can advantageously be used for diagnostics.
  • markers are used.
  • the markers are selected from the markers with the protein ID:
  • the markers are selected from the markers with the protein ID:
  • the markers or a subset of the markers are selected, which are characterized by the following numbers:
  • markers having the following protein ID are used:
  • the markers are selected from the markers with the protein ID:
  • Urine was used to detect polypeptide markers for diagnosis. Urine was withdrawn from healthy donors (peer group) and from patients with kidney disease.
  • proteins such as albumin and immunoglobulins, which are also present in urine of patients in higher concentrations, had to be separated by ultrafiltration.
  • 700 .mu.l of urine were removed and treated with 700 .mu.m filtration buffer (2M urea, 1OmM ammonia, 0.02% SDS).
  • 700 .mu.m filtration buffer (2M urea, 1OmM ammonia, 0.02% SDS).
  • sample volumes were ultrafiltered (20 kDa, Sartorius, Gottingen, DE).
  • the UF was carried out at 3000 rpm in a centrifuge until 1.1 ml ultrafiltrate was obtained.
  • CE-MS measurements were carried out using a Beckman Coulter capillary electrophoresis system (P / ACE MDQ system, Beckman Coulter Ine, Fullerton, USA) and Bruker ESI-TOF mass spectrometer (micro-TOF MS, Bruker Daltonik, Bremen, D).
  • the CE capillaries were purchased from Beckman Coulter, having an ID / OD of 50/360 ⁇ m and a length of 90 cm.
  • the mobile phase for the CE separation consisted of 20% acetonitrile and 0.25% formic acid in water.
  • 30% isopropanol with 0.5% formic acid was used. used here, with a flow rate of 2 ⁇ l / min.
  • the coupling of CE and MS was realized by a CE-ESI-MS sprayer kit (Agilent Technologies, Waldbronn, DE).
  • the duration of the injection was 99 seconds. With these parameters about 150 nl of the sample were injected into the capillary, this corresponds to about 10% of the capillary volume.
  • a "stacking" technique was used, injecting an IM NH 3 solution for 7 sec (at 1 psi) before injecting the sample, and then injecting a 2M formic acid solution for 5 sec after sample injection the separation voltage (30 kV), the analytes are automatically concentrated between these solutions.
  • CE separation was performed with a pressure method: 0 psi for 40 minutes, 0.1 psi for 2 minutes, 0.2 psi for 2 minutes, 0.3 psi for 2 minutes, 0.4 psi for 2 minutes, finally 32 min at 0.5 psi.
  • the total duration of a separation run was thus 80 minutes.
  • the "Nebulizer gas” was set to the lowest possible value.
  • the voltage applied to the spray needle to generate the electrospray was 3700 - 4100 V.
  • the remaining settings on the mass spectrometer were optimized according to the manufacturer's instructions for peptide detection. The spectra were recorded over a mass range of m / z 400 to m / z 3000 and accumulated every 3 seconds.
  • the proteins / polypeptides are each used in a concentration of 10 pmol / ⁇ l in water.
  • REV "REV”, "ELM”, “KINCON” and “GIVLY” represent synthetic peptides.
  • the most probable assignment is that in which there is a substantially linear relationship between the shift for the peptide 1 and for the peptide 2.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé permettant de diagnostiquer une insuffisance rénale aiguë, comprenant une étape de détermination de la présence ou de l'absence ou de l'amplitude d'au moins trois marqueurs polypeptidiques dans un échantillon, le marqueur polypeptidique appartenant aux marqueurs qui sont caractérisés dans le tableau 1 par des valeurs relatives aux masses moléculaires et au temps de migration.
EP10729860A 2009-07-02 2010-07-02 Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë Withdrawn EP2449385A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10729860A EP2449385A1 (fr) 2009-07-02 2010-07-02 Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09164374 2009-07-02
EP10729860A EP2449385A1 (fr) 2009-07-02 2010-07-02 Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë
PCT/EP2010/059444 WO2011000938A1 (fr) 2009-07-02 2010-07-02 Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë

Publications (1)

Publication Number Publication Date
EP2449385A1 true EP2449385A1 (fr) 2012-05-09

Family

ID=42537705

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10729860A Withdrawn EP2449385A1 (fr) 2009-07-02 2010-07-02 Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë

Country Status (6)

Country Link
US (1) US20120118737A1 (fr)
EP (1) EP2449385A1 (fr)
JP (1) JP2012531615A (fr)
AU (1) AU2010267972A1 (fr)
CA (1) CA2766228A1 (fr)
WO (1) WO2011000938A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5351773B2 (ja) * 2007-03-07 2013-11-27 モザイクヴェス ディアグノシュティクス アンド テラポイティクス アクチェン ゲゼルシャフト 尿試料中の検体の濃度を正規化するための方法
EP1972940A1 (fr) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer des maladies des reins
JP2011515672A (ja) * 2008-03-19 2011-05-19 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 腎尿細管の損傷および疾患の診断のための方法およびマーカー
US20110214990A1 (en) * 2008-09-17 2011-09-08 Mosaiques Diagnostics And Therapeutics Ag Kidney cell carcinoma
EP3922990B1 (fr) 2021-03-28 2024-05-08 MS Ekspert Sp. z o.o. Système pour le changement et le scellement automatiques des colonnes chromatographiques jetables en chromatographie liquide à haute performance, procédé de mesure et son application dans l'analyse de biomarqueurs de maladies rares
CN114853853B (zh) * 2022-06-08 2023-08-18 宁波市健康口腔医学研究院 一种口腔癌标志物的完全抗原及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004088276A2 (fr) * 2003-03-27 2004-10-14 Children's Hospital Medical Center Procede et trousse permettant de detecter l'apparition precoce de lesions de cellules tubulaires renales
US20050158801A1 (en) * 2002-12-06 2005-07-21 Renovar Incorporated Systems and methods for characterizing kidney diseases
WO2008017306A1 (fr) * 2006-08-07 2008-02-14 Antibodyshop A/S Test de diagnostic pour exclure une importante lésion rénale
WO2008116867A1 (fr) * 2007-03-26 2008-10-02 Novartis Ag Biomarqueurs rénaux prédictifs sûrs et signatures de biomarqueurs pour surveiller la fonction rénale
WO2010091231A1 (fr) * 2009-02-06 2010-08-12 Astute Medical, Inc. Procédés et compositions pour le diagnostic et le pronostic de lésion rénale et de l'insuffisance rénale
WO2010136059A1 (fr) * 2009-05-26 2010-12-02 Universidad De Salamanca Protéine activatrice de gm2 urinaire en tant que marqueur de l'insuffisance rénale aiguë ou du risque de développer une insuffisance rénale aiguë

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120385T2 (de) 2000-03-30 2007-06-06 Orde Levinson Vorrichtung zum urinieren
DE10021737C2 (de) 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
CN101361001A (zh) * 2006-01-20 2009-02-04 马赛奎斯诊断和治疗有限公司 诊断肾病的方法和标志物
JP2011515672A (ja) * 2008-03-19 2011-05-19 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 腎尿細管の損傷および疾患の診断のための方法およびマーカー

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158801A1 (en) * 2002-12-06 2005-07-21 Renovar Incorporated Systems and methods for characterizing kidney diseases
WO2004088276A2 (fr) * 2003-03-27 2004-10-14 Children's Hospital Medical Center Procede et trousse permettant de detecter l'apparition precoce de lesions de cellules tubulaires renales
WO2008017306A1 (fr) * 2006-08-07 2008-02-14 Antibodyshop A/S Test de diagnostic pour exclure une importante lésion rénale
WO2008116867A1 (fr) * 2007-03-26 2008-10-02 Novartis Ag Biomarqueurs rénaux prédictifs sûrs et signatures de biomarqueurs pour surveiller la fonction rénale
WO2010091231A1 (fr) * 2009-02-06 2010-08-12 Astute Medical, Inc. Procédés et compositions pour le diagnostic et le pronostic de lésion rénale et de l'insuffisance rénale
WO2010136059A1 (fr) * 2009-05-26 2010-12-02 Universidad De Salamanca Protéine activatrice de gm2 urinaire en tant que marqueur de l'insuffisance rénale aiguë ou du risque de développer une insuffisance rénale aiguë

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011000938A1 *

Also Published As

Publication number Publication date
AU2010267972A1 (en) 2012-01-19
CA2766228A1 (fr) 2011-01-06
WO2011000938A1 (fr) 2011-01-06
JP2012531615A (ja) 2012-12-10
US20120118737A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
EP2118667A2 (fr) Procédé et marqueurs pour le diagnostic de maladies renales
EP1287348B1 (fr) Procede et dispositif de determination qualitative et/ou quantitative d'un modele proteique et/ou peptidique d'un echantillon de liquide, preleve d'un corps humain ou animal
EP2338054A1 (fr) Carcinome à cellules rénales
WO2009115570A2 (fr) Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
EP2394171A2 (fr) Maladie polykystique rénale autosomique dominante (adpkd)
EP2449385A1 (fr) Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë
EP2810077A2 (fr) Marqueurs polypeptidiques pour le diagnostic et l'évaluation de l'insuffisance cardiaque
EP2212703A1 (fr) Procédé et marqueurs pour diagnostiquer le diabète sucré
WO2011029954A2 (fr) Polypeptide marqueur pour le diagnostic et l'évaluation de maladies vasculaires
WO2009047280A2 (fr) Marqueur polypeptidique pour le diagnostic du cancer de la prostate
EP1757939A1 (fr) Marqueurs polypeptidiques pour la diagnose du cancer de la vessie
EP1955064A1 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
EP2317320A2 (fr) Marqueurs polypeptidiques pour la diagnose du cancer de la prostate
WO2012076723A1 (fr) Procédé et marqueur pour le diagnostic d'un rétrécissement des voies biliaires et d'un cholangiocarcinome à partir de la bile
WO2012123527A1 (fr) Procédé et marqueurs de diagnostic de formes infracliniques et cliniques du rejet tubulo-interstitiel à médiation lymphocytaire t après une transplantation rénale
WO2013150132A2 (fr) Marqueurs polypeptidiques pour diagnostiquer et évaluer des accidents vasculaires cérébraux
EP1896856A1 (fr) Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce
DE102004042530B4 (de) Verfahren zur Diagnose von Arteriosklerose
EP1869473A2 (fr) Marqueur de polypeptide pour le diagnostic d'alzheimer
EP1955075A2 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer des maladies vasculaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140306

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160105